BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33275754)

  • 1. Identifying potential germline variants from sequencing hematopoietic malignancies.
    Kraft IL; Godley LA
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):219-227. PubMed ID: 33275754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying potential germline variants from sequencing hematopoietic malignancies.
    Kraft IL; Godley LA
    Blood; 2020 Nov; 136(22):2498-2506. PubMed ID: 33236764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.
    DiNardo CD; Routbort MJ; Bannon SA; Benton CB; Takahashi K; Kornblau SM; Luthra R; Kanagal-Shamanna R; Medeiros LJ; Garcia-Manero G; M Kantarjian H; Futreal PA; Meric-Bernstam F; Patel KP
    Cancer; 2018 Jul; 124(13):2704-2713. PubMed ID: 29682723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.
    Drazer MW; Kadri S; Sukhanova M; Patil SA; West AH; Feurstein S; Calderon DA; Jones MF; Weipert CM; Daugherty CK; Ceballos-López AA; Raca G; Lingen MW; Li Z; Segal JP; Churpek JE; Godley LA
    Blood Adv; 2018 Jan; 2(2):146-150. PubMed ID: 29365323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.
    Atluri H; Gerstein YS; DiNardo CD
    Curr Hematol Malig Rep; 2022 Dec; 17(6):275-285. PubMed ID: 36279069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing.
    Cheng DT; Prasad M; Chekaluk Y; Benayed R; Sadowska J; Zehir A; Syed A; Wang YE; Somar J; Li Y; Yelskaya Z; Wong D; Robson ME; Offit K; Berger MF; Nafa K; Ladanyi M; Zhang L
    BMC Med Genomics; 2017 May; 10(1):33. PubMed ID: 28526081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline predisposition to hematopoietic malignancies.
    Feurstein S; Drazer M; Godley LA
    Hum Mol Genet; 2021 Oct; 30(20):R225-R235. PubMed ID: 34100074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline Predisposition in Hematologic Malignancies: Testing, Management, and Implications.
    Godley LA; DiNardo CD; Bolton K
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432218. PubMed ID: 38768412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
    Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R
    PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of targeted next-generation sequencing for the diagnosis of myeloid neoplasms with germline predisposition.
    Andrés-Zayas C; Suárez-González J; Rodríguez-Macías G; Dorado N; Osorio S; Font P; Carbonell D; Chicano M; Muñiz P; Bastos M; Kwon M; Díez-Martín JL; Buño I; Martínez-Laperche C
    Mol Oncol; 2021 Sep; 15(9):2273-2284. PubMed ID: 33533142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I diagnose myeloid neoplasms with germline predisposition.
    Patel N; Calvo KR
    Am J Clin Pathol; 2023 Oct; 160(4):352-364. PubMed ID: 37458302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    Hauke J; Hahnen E; Schneider S; Reuss A; Richters L; Kommoss S; Heimbach A; Marmé F; Schmidt S; Prieske K; Gevensleben H; Burges A; Borde J; De Gregorio N; Nürnberg P; El-Balat A; Thiele H; Hilpert F; Altmüller J; Meier W; Dietrich D; Kimmig R; Schoemig-Markiefka B; Kast K; Braicu E; Baumann K; Jackisch C; Park-Simon TW; Ernst C; Hanker L; Pfisterer J; Schnelzer A; du Bois A; Schmutzler RK; Harter P
    J Med Genet; 2019 Sep; 56(9):574-580. PubMed ID: 30979843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method to reduce ancestry related germline false positives in tumor only somatic variant calling.
    Halperin RF; Carpten JD; Manojlovic Z; Aldrich J; Keats J; Byron S; Liang WS; Russell M; Enriquez D; Claasen A; Cherni I; Awuah B; Oppong J; Wicha MS; Newman LA; Jaigge E; Kim S; Craig DW
    BMC Med Genomics; 2017 Oct; 10(1):61. PubMed ID: 29052513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline Genetic Predisposition to Hematologic Malignancy.
    Furutani E; Shimamura A
    J Clin Oncol; 2017 Mar; 35(9):1018-1028. PubMed ID: 28297620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of Characteristics of Clinical Next-Generation Sequencing-Based Testing for Hematologic Malignancies.
    Zhang BM; Keegan A; Li P; Lindeman NI; Nagarajan R; Routbort MJ; Vasalos P; Kim AS; Merker JD
    Arch Pathol Lab Med; 2021 Sep; 145(9):1110-1116. PubMed ID: 33450747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NGS-based multi-gene panel testing in hematological malignancies: germline variants and related issues].
    Nannya Y
    Rinsho Ketsueki; 2022; 63(4):308-312. PubMed ID: 35491221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers.
    Gupta S; Greenberg S; Grimmett J; Gaston D; Agarwal N; Lowrance W; Schiffman J; Kohlmann W
    Fam Cancer; 2017 Oct; 16(4):545-550. PubMed ID: 28315974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutation panels: Time to clear their names.
    Trottier AM; Cavalcante de Andrade Silva M; Li Z; Godley LA
    Cancer Genet; 2019 Jun; 235-236():84-92. PubMed ID: 31101556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.